We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Halozyme (HALO) Q1 Earnings and Revenues Miss Estimates
Read MoreHide Full Article
Halozyme Therapeutics, Inc. (HALO - Free Report) reported first-quarter 2020 loss of 4 cents per share, wider than the Zacks Consensus Estimate of a loss of 1 cent. The company had reported earnings of 1 cent in the year-ago quarter.
Total revenues declined 55.5% year over year to $25.4 million due to lower royalties and collaboration revenues as well as product sales. The top line also missed the Zacks Consensus Estimate of $39.35 million.
Shares of Halozyme were down 4.1% in after-market trading on May 11, following the earnings release. However, the stock has gained 40% so far this year compared with the industry’s 4.7% increase.
Quarterly Highlights
Halozyme’s top line comprises product sales, royalties and revenues under collaborative agreements.
Royalty revenues were $16.8 million in the first quarter, down 6% from the year-ago quarter. The lower royalties resulted from lower sales of its partnered drugs due to biosimilar competition.
Product sales, solely from the sale of bulk rHuPH20 to collaborators using the ENHANZE platform for drug development, decreased 2.9% to $8.1 million in the first quarter.
Revenues under collaborative agreements were $0.4 million compared with $30.6 million in the prior-year quarter. The significant decline was due to recognition of $30 million upfront payment from argenx (ARGX - Free Report) in the year-ago quarter.
Research and development (R&D) expenses declined 67.6% year over year to $10.2 million mainly due to discontinuation of oncology drug development efforts.
Selling, general and administrative (SG&A) expenses were $12.6 million, down 29.8% from the year-ago period. The decline was due to lower compensation and commercial-related expenses as a result of a restructuring initiatives announced last year.
Business Developments
Earlier this month, the FDA approved the subcutaneous (“SC”) formulation of J&J’s (JNJ - Free Report) blood cancer drug, Darzalex, which will be available as Darzalex Faspro. The new formulation of the blockbuster drug was developed using Halozyme’s ENHANZE technology. The SC formulation of Darzalex is also under review in Europe. Last month, the Committee for Medicinal Products for Human Use recommended its approval in Europe. The company anticipates a European approval in mid-2020.
Moreover, in February, the FDA accepted Roche’s (RHHBY - Free Report) regulatory application seeking approval for subcutaneous administration of the fixed-dose combination of Perjeta and Herceptin utilizing ENHANZE technology. A decision is expected in October. Roche has also submitted regulatory application in Europe for the same.
Meanwhile, the company stated on its earnings call that nine clinical studies that were planned for this year by its collaboration partners using the company’s ENHANZE technology may face a delay of one to two quarters compared to previously anticipated timeline due to COVID-19. However, the majority of the studies will still start in 2020, including the delay. Among the nine planned studies for 2020, a phase II study has already been started by its partner, argenx recently.
2020 Guidance Maintained
Despite the COVID-19 pandemic, Halozyme maintained its view for revenues and earnings in 2020 provided in January. The company expects total revenues in 2020 to be between $230 million and $245 million, indicating year-over-year growth of 17-25%. It expects reported earnings to be in the range of 60-75 cents per share.
Halozyme Therapeutics Inc Price, Consensus and EPS Surprise
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.1% per year.
These 7 were selected because of their superior potential for immediate breakout.
Image: Bigstock
Halozyme (HALO) Q1 Earnings and Revenues Miss Estimates
Halozyme Therapeutics, Inc. (HALO - Free Report) reported first-quarter 2020 loss of 4 cents per share, wider than the Zacks Consensus Estimate of a loss of 1 cent. The company had reported earnings of 1 cent in the year-ago quarter.
Total revenues declined 55.5% year over year to $25.4 million due to lower royalties and collaboration revenues as well as product sales. The top line also missed the Zacks Consensus Estimate of $39.35 million.
Shares of Halozyme were down 4.1% in after-market trading on May 11, following the earnings release. However, the stock has gained 40% so far this year compared with the industry’s 4.7% increase.
Quarterly Highlights
Halozyme’s top line comprises product sales, royalties and revenues under collaborative agreements.
Royalty revenues were $16.8 million in the first quarter, down 6% from the year-ago quarter. The lower royalties resulted from lower sales of its partnered drugs due to biosimilar competition.
Product sales, solely from the sale of bulk rHuPH20 to collaborators using the ENHANZE platform for drug development, decreased 2.9% to $8.1 million in the first quarter.
Revenues under collaborative agreements were $0.4 million compared with $30.6 million in the prior-year quarter. The significant decline was due to recognition of $30 million upfront payment from argenx (ARGX - Free Report) in the year-ago quarter.
Research and development (R&D) expenses declined 67.6% year over year to $10.2 million mainly due to discontinuation of oncology drug development efforts.
Selling, general and administrative (SG&A) expenses were $12.6 million, down 29.8% from the year-ago period. The decline was due to lower compensation and commercial-related expenses as a result of a restructuring initiatives announced last year.
Business Developments
Earlier this month, the FDA approved the subcutaneous (“SC”) formulation of J&J’s (JNJ - Free Report) blood cancer drug, Darzalex, which will be available as Darzalex Faspro. The new formulation of the blockbuster drug was developed using Halozyme’s ENHANZE technology. The SC formulation of Darzalex is also under review in Europe. Last month, the Committee for Medicinal Products for Human Use recommended its approval in Europe. The company anticipates a European approval in mid-2020.
Moreover, in February, the FDA accepted Roche’s (RHHBY - Free Report) regulatory application seeking approval for subcutaneous administration of the fixed-dose combination of Perjeta and Herceptin utilizing ENHANZE technology. A decision is expected in October. Roche has also submitted regulatory application in Europe for the same.
Meanwhile, the company stated on its earnings call that nine clinical studies that were planned for this year by its collaboration partners using the company’s ENHANZE technology may face a delay of one to two quarters compared to previously anticipated timeline due to COVID-19. However, the majority of the studies will still start in 2020, including the delay. Among the nine planned studies for 2020, a phase II study has already been started by its partner, argenx recently.
2020 Guidance Maintained
Despite the COVID-19 pandemic, Halozyme maintained its view for revenues and earnings in 2020 provided in January. The company expects total revenues in 2020 to be between $230 million and $245 million, indicating year-over-year growth of 17-25%. It expects reported earnings to be in the range of 60-75 cents per share.
Halozyme Therapeutics Inc Price, Consensus and EPS Surprise
Halozyme Therapeutics Inc price-consensus-eps-surprise-chart | Halozyme Therapeutics Inc Quote
Zacks Rank
Halozyme currently carries a Zacks Rank #2 (Buy).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.1% per year.
These 7 were selected because of their superior potential for immediate breakout.
See these time-sensitive tickers now >>